6 completed, 5 unknown, 2 recruiting, 1 enrolling by invitation. 9 Phase 1, 5 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 5, Unknown 3, Recruiting 1 |
| Phase 2 | 5 | Recruiting 2, Completed 1, Enrolling by invitation 1, Unknown 1 |
| Phase 3 | 1 | Unknown 1 |
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC HB0025 20 mg/kg plus nab-paclitaxel, HB0025 10 mg/kg plus nab-paclitaxel - TNBC | Phase 2 | Enrolling by invitation | Huabo Biopharm Co., Ltd. | 60 | 2025-08-14 | 2026-01-29 |
| A Phase 2 Study of HB0017 in Psoriasis Patients HB0017 - Psoriasis (PsO) | Phase 2 | Recruiting | Huabo Biopharm Co., Ltd. | 200 | 2024-09-30 | 2025-09-15 |
| Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis HB0017 Q4W, HB0017 Q8W, placebo - Psoriasis | Phase 3 | Unknown | Huabo Biopharm Co., Ltd. | 400 | 2024-03-01 | 2024-06-27 |
| A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor HB0025, Pemetrexed, Paclitaxel - Advanced NSCLC, Advanced Endometrial Cancer | Phase 1 / Phase 2 | Recruiting | Huabo Biopharm Co., Ltd. | 282 | 2024-01-31 | 2025-01-23 |
| A Study of HB0025 Injection in Patients With Advanced Renal Cancer HB0025 - Renal Cancer | Phase 2 | Unknown | Huabo Biopharm Co., Ltd. | 100 | 2023-01-30 | 2024-01-24 |
| A Study to Evaluate the Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis Placebo, HB0017 - Plaque Psoriasis | Phase 2 | Completed | Huabo Biopharm Co., Ltd. | 160 | 2022-10-25 | 2024-06-21 |
| A Study of HB0030 Injection in Patients With Advanced Solid Tumors HB0030 injection - Advanced Solid Tumor | Phase 1 | Unknown | Huabo Biopharm Co., Ltd. | 36 | 2021-12-21 | 2023-01-31 |
| A Study of HB0017 in Patients With Moderate to Severe Plaque Psoriasis HB0017 150mg or matching placebo, HB0017 300mg or matching placebo, HB0017 450mg or matching placebo - Plaque Psoriasis | Phase 1 | Completed | Huabo Biopharm Co., Ltd. | 30 | 2021-09-02 | 2022-07-07 |
| A Study of of HOT1030 in Patients With Advanced Solid Tumors HOT-1030 - Solid Tumor, Adult | Phase 1 | Completed | Huabo Biopharm Co., Ltd. | 30 | 2021-03-12 | 2026-10-20 |
| A Study of Injection HB0025 in Patients With Advanced Solid Tumors HB0025 - Tumor, Subjects | Phase 1 | Unknown | Huabo Biopharm Co., Ltd. | 154 | 2021-03-10 | 2022-06-01 |
| A Study of Injection HB0017 in Adult Healthy Volunteers HB0017, placebo - Healthy Subjects | Phase 1 | Completed | Huabo Biopharm Co., Ltd. | 40 | 2020-10-02 | 2021-07-28 |
| A Study of HB002.1T Plus Chemotherapy in Subjects With Solid Tumor HB002.1T, Oxaliplatin, Capecitabine - Solid Tumor | Phase 1 | Unknown | Huabo Biopharm Co., Ltd. | 72 | 2020-04-28 | 2021-07-28 |
| A Study of Injection HB002.1T in Subjects With Solid Tumor HB002.1T - Solid Tumor | Phase 1 | Completed | Huabo Biopharm Co., Ltd. | 27 | 2018-06-28 | 2021-07-28 |
| A Study of Single Intravitreal Injection HB002.1M in Subjects With Neovascular Age-Related Macular Degeneration HB002.1M - Neovascular Age-Related Macular Degeneration | Phase 1 | Completed | Huabo Biopharm Co., Ltd. | 21 | 2018-02-08 | 2020-07-29 |
Psoriasis (2) · Endometrial Neoplasms (1) · Kidney Neoplasms (1) · Neoplasms (1)
Carboplatin (2) · Paclitaxel (2) · 130-nm albumin-bound paclitaxel (1) · Capecitabine (1) · Cisplatin (1) · Gemcitabine (1) · Oxaliplatin (1) · Pemetrexed (1)
China (13) · New Zealand (1) · United States (1)
Caicun Zhou, PhD. (1) · Congjun Jiang, Master (1) · Dingwei Ye, MD/PHD (1) · Han Baohui, Doctor (1) · Jianzhong Zhang, MD (1) · Jin Li, Ph.D (1) · Jundong Li, PhD. (1)